← All trials
NCT06502171
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2025
- Primary completion
- Jan 1, 2032
- Completion date
- Jan 1, 2033
- First posted
- Jul 16, 2024
- Last posted
- Oct 10, 2024
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of PennsylvaniaCollaborator
- Department of DefenseCollaborator
- Indiana UniversityCollaborator
- University of Alabama, BirminghamSponsor investigator
- University of Alabama, BirminghamOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.